Related Experiment Videos
Enhancement of antitumor immunity by CTLA-4 blockade
D R Leach1, M F Krummel, J P Allison
1Cancer Research Laboratory, University of California, Berkeley, CA 94720, USA.
Abstract:
One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.
Insights
Blocking CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) with antibodies can overcome tumor immune evasion. This approach leads to tumor rejection and establishes long-term immunity against cancer cells.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Tumor immunogenicity is often poor due to insufficient T cell costimulation signals.
- Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) acts as a negative regulator of T cell activation.
- CTLA-4 interacts with B7 family molecules, inhibiting immune responses.
Purpose of the Study:
- To investigate the potential of blocking CTLA-4 to enhance anti-tumor immunity.
- To determine if CTLA-4 blockade can induce rejection of established tumors.
- To assess if tumor rejection mediated by CTLA-4 blockade confers secondary immunity.
Main Methods:
- In vivo administration of antibodies targeting CTLA-4.
- Monitoring tumor rejection in animal models.
- Assessing immune response to secondary tumor cell exposure.
Main Results:
- Antibodies to CTLA-4 induced rejection of tumors, including pre-established ones.
- Tumor rejection was associated with the development of immunity to subsequent tumor cell challenges.
- Blockade of CTLA-4's inhibitory signals potentiated effective anti-tumor immune responses.
Conclusions:
- CTLA-4 blockade is a promising strategy for enhancing anti-tumor immunity.
- Overcoming CTLA-4-mediated suppression can lead to durable tumor rejection and protective immunity.
- Targeting CTLA-4 offers a potential therapeutic avenue for cancer treatment.